Seer Inc represents values of innovation, transparency, and collaboration. As a cutting-edge biotechnology company, Seer Inc operates with a corporate philosophy centered around advancing healthcare through transformative technologies. The company is committed to improving patient outcomes by developing novel solutions for understanding biology and enabling earlier disease detection. With a focus on data-driven insights and interdisciplinary approaches, Seer Inc fosters a culture of scientific excellence and teamwork. By aligning their vision with market needs, Seer Inc aims to revolutionize the field of proteomics and contribute to the future of precision medicine.

Seer Inc is primarily present in the United States.

Seer Inc, a leading company in the stock market, has achieved significant milestones in its journey. Notably, Seer Inc successfully completed its initial public offering (IPO), raising substantial capital to fuel its growth and expansion initiatives. The company has also received recognition for its breakthrough innovations and cutting-edge technologies in the field of stock trading. Furthermore, Seer Inc has successfully forged strategic partnerships with renowned industry players, strengthening its market position and enhancing shareholder value. With a strong commitment to delivering exceptional investment services, Seer Inc continues to revolutionize the stock market landscape, making it a highly promising investment option for individuals seeking sustainable financial growth.

Seer Inc. is a leading life sciences company specializing in proteomics. Founded in 2017, the company aims to improve human health by enabling scientists to understand the dynamic world of biology through its innovative technologies. Seer's platform leverages the power of proteomics, a study of proteins, to provide deep insights into complex biological processes and diseases. Through its powerful proprietary technologies, Seer has gained recognition for its ability to analyze large-scale proteomic data sets accurately. With a team of experienced scientists and cutting-edge technology, Seer Inc. is poised to revolutionize the field of proteomics and contribute to advancements in healthcare.

The main competitors of Seer Inc in the market include major players like Thermo Fisher Scientific, Agilent Technologies, and Waters Corporation.

Seer Inc is primarily active in the biotechnology and life sciences industries.

Seer Inc's business model revolves around developing and commercializing proprietary Proteograph™ technology to enable researchers in the life sciences field to gain deep insights into the proteome. By leveraging their expertise in mass spectrometry, data science, and bioinformatics, Seer Inc aims to revolutionize protein analysis and provide researchers with comprehensive insights into the proteome. With its innovative platform, Seer Inc offers powerful solutions to accelerate discoveries in various applications, such as drug discovery, diagnostics, and precision medicine. Through its cutting-edge technologies, Seer Inc strives to empower scientists and catalyze advancements in proteomics research.

Seer hissesinin F/K oranı -1,31.

Seer KUV 6,78 dir.

Seer için AlleAktien Kalite Skoru 4/10'dur.

beklenen Seer cirosu 18,39 Milyon. USD dir.

beklenen Seer karı -95,24 Milyon. USD olarak gerçekleşmiştir.

Seer Inc is a fast-growing company specializing in providing advanced imaging and diagnostic technology for the healthcare industry. The company started with the development of visualized data analytics and tools for data analysis and modeling, and has now expanded its activities to various sectors. One of the key sectors of Seer Inc is the development of computed tomography machines equipped with high-resolution scanners and powerful algorithms. These scanners are used in medical facilities such as hospitals and clinics to provide accurate and fast diagnoses and assist in surgical procedures. The company also offers solutions for mammography specifically designed for breast cancer prevention and diagnosis. Seer Inc mammography machines utilize advanced technologies such as digital image processing and layer imaging to provide accurate results without causing unnecessary radiation exposure to the patient. Seer Inc also offers advanced imaging products for molecular imaging. These products include in-vivo and in-vitro imaging systems tailored to various scientific applications and research areas. The company also collaborates closely with academic research institutions to develop innovative imaging solutions for intensive research and development in the healthcare industry. In addition to the aforementioned products and sectors, Seer Inc also provides technical services to its customers, including maintenance and repair services. The company is committed to providing comprehensive and reliable support to its customers to ensure the maximum lifespan of the products and ensure the highest level of patient care. The business model of Seer Inc is driven by its focus on continuous innovation and research. The company is always striving to develop new technologies and products to better meet the needs of its customers and improve healthcare worldwide. Seer Inc works closely with leading research institutions and medical professionals to ensure that its products meet the highest standards and meet the needs of patients and medical professionals. Overall, Seer Inc is a leading company in the healthcare industry, offering innovative imaging solutions for a variety of applications and research areas. The company is dedicated to providing excellent service and top-notch products to its customers to ensure the highest quality of patient care and advance the healthcare industry worldwide.

Seer, yılda kez dağıtılmak üzere 0 USD tutarında temettü ödemektedir.

Seer için şu an için temettü hesaplanamıyor veya şirket temettü dağıtmıyor.

Seer şirketinin ISIN kodu US81578P1066’dir.

Seer için Ticker SEER’dir.

Son 12 ay içerisinde Seer, tutarında bir temettü ödedi. Bu, yaklaşık olarak oranında bir temettü verimine denk gelmektedir. Gelecek 12 ay için Seer, tahmini olarak 0 USD tutarında bir temettü ödemesi yapacak.

Seer şirketinin mevcut temettü verimi .

Seer dönemsel olarak temettü ödemesi yapar. Bu ödemeler aylarında gerçekleştirilir.

Seer, son 0 yıl içerisinde her yıl temettü ödedi.

Önümüzdeki 12 ay için 0 USD tutarında temettü ödenmesi beklenmektedir. Bu, 0 % oranında bir temettü verimidir.

Seer, 'Sağlık' sektörüne atanmıştır.

Son Seer tarihinde 0 USD tutarındaki en son temettüyü alabilmek için, hisseyi 07.03.2025 tarihindeki Ex-Tag'den önce portföyünde bulundurman gerekiyordu.

Son ödeme tarihi 07.03.2025 olarak gerçekleşti.

2024 yılında Seer tarafından 0 USD olarak temettüler dağıtıldı.

Seer hisselerinin temettüleri USD olarak dağıtılır.